These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33915021)

  • 41.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
    Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
    [No Abstract]   [Full Text] [Related]  

  • 43. A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.
    Zhao H; Wang Y; Yin ETS; Zhao K; Hu Y; Huang H
    Front Med; 2020 Dec; 14(6):711-725. PubMed ID: 33259039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications.
    Blache U; Weiss R; Boldt A; Kapinsky M; Blaudszun AR; Quaiser A; Pohl A; Miloud T; Burgaud M; Vucinic V; Platzbecker U; Sack U; Fricke S; Koehl U
    Front Immunol; 2021; 12():658314. PubMed ID: 34012442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
    Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
    Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hematopathologic Correlates of CAR T-Cell Therapy.
    Dolan JG; Paessler ME; Rheingold SR; Pillai V
    Clin Lab Med; 2021 Sep; 41(3):325-339. PubMed ID: 34304768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
    Tan AP
    Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immunotherapy with CAR-T cells in paediatric haematology-oncology].
    Mirones I; Moreno L; Patiño-García A; Lizeaga G; Moraleda JM; Toribio ML; Pérez-Martínez A; ;
    An Pediatr (Engl Ed); 2020 Jul; 93(1):59.e1-59.e10. PubMed ID: 32107177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells.
    Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C
    Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
    Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
    Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
    Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
    Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
    Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
    J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.
    Havard R; Stephens DM
    Curr Hematol Malig Rep; 2018 Dec; 13(6):534-542. PubMed ID: 30362020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 59. Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies.
    Guercio M; Manni S; Boffa I; Caruso S; Di Cecca S; Sinibaldi M; Abbaszadeh Z; Camera A; Ciccone R; Polito VA; Ferrandino F; Reddel S; Catanoso ML; Bocceri E; Del Bufalo F; Algeri M; De Angelis B; Quintarelli C; Locatelli F
    Front Immunol; 2021; 12():755639. PubMed ID: 34737753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.